# Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)

> **NCT05323435** · PHASE2 · COMPLETED · sponsor: **Jiangsu Rec-Biotechnology Co., Ltd.** · enrollment: 300 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Recombinant two-component COVID-19 vaccine (CHO cell)
- **BIOLOGICAL:** COVID-19 Vaccine (Vero Cell), Inactivated

## Key facts

- **NCT ID:** NCT05323435
- **Lead sponsor:** Jiangsu Rec-Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-30
- **Primary completion:** 2022-07-05
- **Final completion:** 2023-01-16
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2023-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05323435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05323435, "Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05323435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*